Tag: SHPH Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares are witnessing a significant surge on the US stock charts following the announcement of the completion of site enrollments for a crucial clinical trial. As of the latest pre-market check, SHPH shares were trading at $2.01, reflecting an impressive increase of 52.27%.

Clinical Trial Agreements Finalized

Shuttle Pharma (SHPH) has successfully signed contracts with each of the six approved sites for the Phase 2 clinical study of ropidoxuridine, which is meant to treat patients with glioblastoma.

In addition to previous agreements with prestigious organizations like the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN) Cancer Institute, and Miami Cancer Institute, which is a part of Baptist Health South Florida, the newly formed partnerships include Georgetown University Medical Center and UNC Medical Center. Currently, patients are undergoing screening processes for trial enrollment.

Ropidoxuridine: A Promising Candidate

Ropidoxuridine (IPdR) is recognized as Shuttle Pharma’s lead candidate, intended to serve as a radiation sensitizer in conjunction with standard radiation therapy (RT) for glioblastoma treatment. This aggressive brain malignancy is particularly challenging, with no established cure available. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IPdR, which could offer marketing exclusivity upon its first approval for the treatment of this condition.

The Significance of the Clinical Trial

The Phase 2 clinical trial is set to enroll patients diagnosed with aggressive, IDH wild-type, methylaion-negative glioblastomas. Standard treatment currently involves radiation therapy; however, research indicates that over half of the patients in this demographic may not survive beyond 12 months post-diagnosis.

In the U.S., approximately 800,000 patients receive radiation therapy annually, with an estimated 400,000 undergoing treatment aimed at curative outcomes. The trial’s findings will be vital for the oncology community, as Shuttle Pharma seeks to identify effective radiation sensitizers to enhance cure rates, extend survival, and improve the overall quality of life for glioblastoma patients.

Shares of Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) are rising on US stock charts today following the company’s release of a corporate update. Shuttle Pharma stock was up 10.55% to $2.62 as of the most recent pre-market check.

Shuttle Pharma Showed Progress in a Clinical Trial

In conjunction with the submission of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024, Shuttle Pharma (SHPH) offered a corporate update. After successful agreements with two first site locations, the trial has started, with six planned sites expected to be operational soon. The objective of the Phase 2 trial is to assess the radiation sensitization efficacy of ropidoxuridine in order to improve treatment results for individuals suffering from this difficult cancer.

Strategic Turning Points and Regulatory Developments

Apart from the trial’s advancement, Shuttle Pharmaceuticals has received FDA Orphan Drug Designation. This designation highlights the importance of the company’s novel approach to treating glioblastoma and offers prospective marketing exclusivity following FDA clearance.

The two initial trial sites have completed all preparatory steps and are poised to start patient enrollment. The trial will focus on patients with IDH wild-type, methylation negative glioblastoma, who currently face a bleak prognosis with radiation therapy being the only approved standard of care.

SHPH: Future Expectations and Trial Duration

Shuttle Pharmaceuticals anticipates that the Phase 2 trial will be conducted over an 18 to 24-month period. The study will first determine the optimal dosage of Ropidoxuridine, with an additional 14 patients to be enrolled at this dose to achieve statistical significance regarding survival rates compared to historical controls.

This critical research aims to improve survival rates and quality of life for glioblastoma patients, advancing SHPH’s mission to enhance cancer treatment efficacy while minimizing radiation’s late effects. Through these significant advancements, Shuttle Pharmaceuticals is making strides toward its goal of revolutionizing cancer care and offering new hope to patients battling glioblastoma.